| Founded | 2010 |
|---|---|
| Closed | 2024 |
| Country | USA |
| Sector | Biotech |
| Collapse type | Zombie Startup |
bluebird bio
"The gene therapy pioneer that spent 14 years and 4B dollars developing cures for rare diseases and became a zombie when payers refused to cover the 2.8M dollar price tag."
Technically alive but effectively dead, burning cash
Key Events Timeline
bluebird bio developed gene therapies for sickle cell disease (Lyfgenia, $3.
// full analysis
Full analysis requires the Analyst plan
Documented cause · Market cycle · Competitive moat type · Verified lesson
€149/mo · or contribute your autopsy for free access →
UnicornBurn Season 0 opens July 2026. 10,000 founders competing in one world. Your startup fights for the market every Saturday. Most will end up here. Which one are you?
JOIN SEASON 0 →bluebird bio followed a documented pattern. Identify the same signals in any company before they reach the point of no return.
Witnessed a startup failure first-hand? Share the real story. First-hand accounts from founders and team members get prioritized for publication.
SUBMIT AN AUTOPSY →Failure intelligence for due diligence and risk analysis.
Structured dataset by collapse type, for 5031 startups. 7-day trial.
See plans →Free JSON API. No key required. 50 autopsies, 10 req/day.
Full dataset available with Intelligence plan API key. CORS enabled.
Explore API →Academic, press, or research use? Free JSON API available — no auth required →